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An|ithrombin Ill Hamilton i* a structural variant ol'antithrombin Ill (AT-Ill) with normal h,purin atl]nity but impaired serine protease inhibitory 
activity, The molecular def~t or AT.Ill.Hamilton is a substitution ofthreonine for aMnine at ~tmtno acid residue ~I~2. R~zently it has be.en shown 
thai both ph;sma.derivcd and ¢ell.rr~©.derivcd AT;lll.|lamiltoi~ polypeptld©~ act as substrate~ rather than inhibitor,~ o( thrombln and (actor X~ll 
in th, present StUdy, the cell.free xpression phagemid vector pGEM.3Zf(+).AT-III I =,~= was mutated at amino acid residue ;11~2 of AT.Ill to 
generate 7 call.free.derived variants, All these cell.free.derived AT-Ill variants were .ble to bind heparin as effectively as cell,free.derived norm,l 
AT.Ill, In terms of =.thrombin inhibitory activity each vitriant reacted differently. Varhtnts could be grouped into 3 categories with respect to 
thrombin-AT-Ill complex formation', (I) nettr normal activity (gly,,:ine, isoleucine, leu¢ine, valia©); (2} low m:tivity (threonine, ghttamine); O) no 
delectable activity (lysine), Their data suggest that n'~utations at position 382 of AT.Ill may have ~t variable ffect on protease inhibitory activity, 
depending on either the stability of the Pta~,P. region er the exposed Mop of'AT;I lL or the inability ot' tltem~nino =tei,tl r©sidue ~t po~ition 382 
tO interact with a conserved hydrophobi ~ pocket ¢onsiatinil or phenylalunine (at positions '77, 221 and 4:22) and isoteueine (position 412) residues, 
Antithrombln III; Hcparin; ,t-Thrombin 
1.  INTRODUCTION 2, MATERIALS  AND METHODS 
2, I, Materials 
Hut'nan ant i th rombin  l l l  (AT - I l l )  is a single-chain All restriction enzymes, T4 DNA polyn~erase, T4 DNA ligase and 
p lasma g lycoprote in  consist ing of  432 amino acids, It is T7 RNA polymerase welle purchased from either Pharm ~c a LKB 
the major  phys io log ica l inh ib i to r  f th rombin  as well as  Biot~clinology (Ouie d Orf¢~ Quebec) o r  BetiieSda ReSearch 
o ther  ser ine proteases o f  the  intrinsic coagulat ion Laboratories (Burlington, Ontario), Modified T7 DNA polymerase 
pathway [I ,2]. AT - I I I  shares both structural  and func- 
t ional  homology  with other  members  o f  the superfami ly  
o f  prote ins known as the serine protease inhibitors,  or 
serpins, 
The phys io log ica l  importance o f  AT- I I I  is 
demonst ra ted  by individuals with heredi tary AT- I l l  
def ic iency who often suffer f rom recurrent h romboem-  
boiSe disease [3,4"1, Character izat ion  of  the genetic 
was purchased from U.S. Biochemicals (Cleveland, OH). The cell- 
free expression vector pGEM.3Zf( + ) nnd rabbit reticulocyte lysate 
(RRL) were purchased from Promega.Biotec (Toronto, Ontario). 
Human thrornbh~ (> 3000 NIH unils/mg; > 99% active) was kindly 
provided by DrJ .  Fenton (New York State Division of Biologieals, 
Albany, NY). All other chemicals and reagents were of the highest 
quality available. 
2.2. Site-directed mutogenesis of Aid.382 
E.co/i DHSc~F' cells containing the pGEM-3Zf(+).AT.IIII..~:~ 
" t3atien s ith A d ' ' v '  ' t a construct [7] were infected WithMI3K07 helper phage to yelds ogle- defects m .. . . . . .  t_ w . . . . .  T - I l l  . .eflclenc lndtca_es th_t .......... . . . . . .  
. . .  - L . . . . . . . . . .  - .... :, . . . .  stranded DNA for site-directed nmtagenesis. Site-directed eel tam o.etlClencles can De attrlDute(:t to point  mutat ions mutagenesis was performed essentially as described by Taylor et al. 
Within the AT- I I I  gene. One such var iant,  AT- I l l -  
Hami l ton ,  conta ins  threonine subst i tuted for alanine at 
amino  acid res idue 382 [5]. Recently AT- I l l -Hami l ton  
has been demonst ra ted  to act as a serine protease  
substrate,  but  not as  an inhibi tor  [6]. In  this com- 
mun icat ion ,  we report  on Site'directed mutagenesis of  
amino  acid residue 382 and its effect on the functional 
act ivity of  AT- I l l .  
Correspondence address: M.A. Blajchmaa, Department of 
Pathology, Room 2N31, McMaster University Medical Centre, 1200 
Main Street West, Hamilton, Ontario LgN 3Z5, Canada 
[8] using the Amersham (Oakville, Ontario) mutagenesis kit. Tile 
oligodeoxyribonucleotide primers were synthesized at the Institute for 
Molecular Biology and Biotechnology, McMaster University 
(Hamilton, Ontario). The mixed 20-mer oligodeoxyribonuele0tide 
primer 5'-GGCAGTGAANNAGCTGCAAG.3' complimentary to 
the Aid-382 region was synthesized such that the first two nucleotide 
positions (represented bythe letter N), corresponding tothe Aid-382 
codon, could be altered randomly, The second position, however, 
corresponding to the Ala-382 codon contained either nucleotides A, 
G, or T. The AT-Ill-Hamilton variant was synthesized as previously 
. dqscribed [61. After duplex formation and phosphorothioate enrich- 
meat, the plasmid DNA was transformed into E. coli DHScz ceils. 
Authenticity of these mutations was confirmed by double-stranded 
DNA sequencing using the chemicMly n~odified T7 DNA polymerasc 
method of Tabor and Richardson [9], The 18.mer oligodeox- 
yribonucleotide primer 5'-GTCTCAGATGCATTCCAT-3' was us- 
ed for sequencing and is situated 36 bp from the first nucleotide posi- 
ti0n encoding Aid-382 Of AT-Ill. 
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2,~, ¢'¢tt,jr¢¢ exptc.¢~imt ~ nure~;d mid v,~rt~nl juuns q[ A T, III 
C¢ll,fr¢~' Itan~rlplk~n, lf~ndallc~n w~ tarried ~ut a~ prevtou~lx 
d,c~rib¢d I"/i. ~1~¢ traa~lallon mi.xlur,/~ ¢onlainlnlt the ¢¢11,fr¢~ [~r'  
~d A'r.III pol~p~pltdes labelled whls I~Slm¢lhlonin¢ were diluted 
l~vO, fold l:a 0.04 hi Tri~,HCI, p l l  '~,~, O.1 NI N~CI, ¢~nlriful~¢d at 
i ~O000 ~ ~ tl~¢kmafl TL . I® ultra~-¢ntril'u~(} rot I h ~t 4~C allalli,,ll 
0,02 M Tri~,14Cl, p l l  7,$, 0.I$ M Nat'l,  TII~ Ir~Insl~lllot~ ll~islllrls 
~r¢  lh~n u~¢d Immcdlatdy, 
Z,4, tlepartn ~flnily und Ihrmnbilt complex J~tmotl~n of ¢¢11,ft¢¢, 
derlvgd marmol and vltrlolt? forltl~t of A T, l l l  
The abllltF ofcdl,tre¢,dcrlved AT- I l l  pol~,~pcplId~ to bind 1~parln 
and form ,coy alert! ¢omplc~e~ with n-lbronlblrl wire ltss¢~sed a~ 
d~'r ib~d prcvit~u~ly 17). Th< ['Slm¢thlonhz~-Iabdled wr ,  i l l  
polypeptid¢~ were analyted bySDS.PAGE 1101 under reductn8 condi. 
tton~ 11 II followed by Iquoro~raph~, Densttom~:;rtc ~¢annlu~ of the 
aut0r~diollram~ wa~ performed using the Hocrfcr GS~00 ffan~mlt, 
tnnce:reflcctunce scannlnl~ tlensilofl~eter and ll~e GS)S0 data SySl¢Itl 
(Hocfr'er Scientific, San Francisco, CA}. 
3, RESULTS 
amino acid substitution or aspartic acid,  winch 
represented one of the possible sobslitutions, WaS not 
identified. In addition, there w~re no stop ¢odon 
substitutions identified at position 382. All of the ceil- 
free-derived 382-variants of AT-Il l  were espress~d effi- 
ciently anti had the same apparent molecular mass as 
cell-free-derived normal AT-Ill (47 kDa), described 
pre~iously [71. 
3.2, HeparimSepharose ehromatogrup/Lv 
The cell-free-derived normal AT.I I l t . .~z and 
382.variants of AT-III showed similar heparin binding 
profiles, Densitometrie scanning fore,lied that approx- 
imately 60-70% of the cell-free-derived normal, and the 
382-variants of AT-Ill bound to the heparin-Sepharose 
column and ehtted as a major peak between 0,2-0,7 M 
NaCI (data not shown), This is also consistent with 
pre~,iously published data [71. 
3,1, ldentification of  the A T.IH varlunts at amino actd 
residue 382 
Following site-directed mutagenesis, double-stranded 
phasn'ta DNA isolated from 24 randomly selected 
transformed colonies containing the 1.5-kb AT-Ill 
eDNA insert was sequenced. Site-directed mutagencsis 
resuRed in the synthesis of 6 unique amino acid sub- 
stitutions at position 382, The 6 unique substitutions 
were glutamine, glycine, isoleucine, leucine, lysin¢ and 
ratine, The AT.llI-Hamilton variant (alanine-382 --. 
threonine) has been synthesized previously [61, An 
3,3, Thrombin-A 7".111 (TA TJ complex fotvnation 
To compare the protease inhibitory activity of the 7 
cell, free-derived 382-variants of AT-Ill, a i00.molar 
excess of human cx.thrombin was added to the transla- 
tion mixtures (contair, ing tl~e radiolabellcd AT-Ill 
polypeptides), Under ".he conditions used, thrombin- 
AT-Ill (TAT) formation peaked at approximately 10% 
within 2 rain, Beyond this time point, however, the 
complexes dissociated (data not shown), Table I sum- 
marizes the relative amount of  TAT complexes formed 
after 2 rain by the ceil-free-derived 382 variants and t~. 
Table I 
Properties of the AT.Ill 382-variants 
Cell.free clerived 382,,variants of AT.Ill were incubated with a 100.molar excess of human eY-thrombin at 370C, Aliq uots of the reaction mixtures 
were terminated with PPACK al~d the radiolabelled protein bands analyzed b~ SDS.PAGE followed by fluorography. TAT formation at 2 rain, 
incubation was qttantitated by densiton~etric s anning of the autoradiogrant and normalized to wild type cell-free.derived TAT corer)loxes, 
Hydrophobicity of a particular amino acid residue was determined by its relation between area buried upon folding and standard state area [14], 
Amino acid substitution Side group structure Residue " volumc(h ~) Hydrophobicity t' Relative (TAT)" l'ormation 
Ala (wry ~ -CH.~ 92 
ILe -CH-CHz-CH.a 169 
CH 
Leu -CH.,-CH-CH.~ 168 
I 
CH~ 
Val -CH-CH~ 142 
C 1--t.~ 
(31y -H 66 
Gin -CH_,-CH~-C = 0 161 
I 
NH2 
Thr -CH-OH 122 
CHj 
Lys -CH z.CH2-CH2-CH2-NH3 ~ 171 
I 
0,83 
0,52 
0,73 
"I- ,0,- 0,61 
+ 0,21 
0 0,09 
.+ - < 0.008 
(--) strongly hydrophobic; (-) moderately hydrophobic; (0) moderately polar; +) hydropllilic; ( -  - ) strongly hydrophilic 
aRef. 12.13 ~Ref, 14 ¢TAT, thrornbin-AT-lll complex dwt, wild type 
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thrombin; normalized to cell-flee.derived normal AT- 
Ill. The d~ta indicate that normal cell-free.derived AT- 
Ill I'ormed the most TAT complexes within 2 rain. The 
substitution of alanine-382 by tile strongly hydropl~obi¢ 
residues isoleucine, leucine or valine produced 0.83, 
0,$2 and 0,73 times the amount TAT formed by the cell- 
free-derived normal AT-I l l ,  respectively. The neutral 
substitution glycine, produced 0.61 times the amount of 
TAT produced by cell free.derived normal AT-III while 
the slightly hydrophilic substitution glutamine resulted 
in 0.21 times the amount. The substitution of threonine 
produced only 0.09 times the amount of  TAT produced 
by cell-free-derived normal AT-III. However, the 
substitution of the strongly hydrophilic residue lysine 
resulted in no detectable TAT complex formation after 
2 rain, The addition of unfractionated heparm at 0.2 
U/mi  increased the rate of TAT formation but did not 
increase the relative amount of TAT formed, 
The data presented in Table I indicate that amino 
acid residue volume effects are minimal, The substitu. 
tions of isoleucine, leucine or valine at position 382, 
which are approximately 35-40% larger than alanine, 
gave similar amounts of TAT  complexes to that obtain- 
ed with cell-free-derived normal AT-I l l ,  However, the 
substitution of  lysine at position 382, which is highly 
hydrophilic and has approximately the same residue 
vohtmc as isoleucine and leucine, caused a dramatic 
decrease in TAT complex formation. Despite its im- 
paired thrombin inhibitory activity this cell-free-derived 
variant was readily cleaved by o~-thrombin (presumably 
at the reactive centre o f  AT-IID, as were all the other 
variants. 
4. DISCUSSION 
Recently, the  natura l  variant AT, l i t .Hamilton 
(alanin¢-382 .~ threonine) was shown to act as n 
substr~te rather than an inhibitor or c¢.thrombin and 
factor Xa 161, This was observed also with cell.free. 
derived AT-I l l -Hamilton [61, This dam, togethe~ with 
the results previously reported for AT-ll l.Charleville 
1151, AT-I l l -Cambridge [16] and AT-l l l=Sudbury [171, 
which contain the substitution of alanine to proline at 
position 384, strongly suggest hat substitutions at or 
near position 382 alter the reactive centre loop such that 
AT-II I  functions as a substrate, but not as an inhibitor 
o f  the striae proteases. The mechanism(s) responsible 
for this inhibitor to substrate conversion have not been 
precisely determined. We report herein on the site- 
directed mutagenesis of  codon 382 of AT-I l l  and ex- 
amine the effect of the substitution of  various amino 
acid residues on tl~e functional activity of cell-free, 
derived AT-III. 
The heparin affinity profiles of cell-free.derived nor- 
mal AT-I l l  and the 382-variants eluted of f  hepartn- 
Sepharose were indistinguishable from each other. This 
is in agreement with previously published data in- 
dicating that the naturally occuring variant, AT-Il l- 
Hamilton, had heparin binding properties identical to 
plasma-derived normal AT.I l l  [5], Thus, amino acid 
substitutions at position 382 do not appear to alter the 
ability of  AT-I l l  to bind to heparin, 
Rose et al, [ 14] showed that the average area of an 
anaino acid residue buried within a known globular pro- 
tein, such as AT-I l l ,  could be accurately correlated with 
. ; .• h. ¸"¸  ¸ "'L ¸¸  ¸ : ",:-h/ - h.- 
P15 
i. hnt£thrombin Ill Gly Set Glu 
2, Heparin Cofaegor IX Gly Thr Gin 
3. Alpha-l-Anelplasmln GI y Val Glu 
4, Plaslninogen 
Ace£vat0r Inhibitor Gly Thr Va l  
5, Pro=tin C Inhibitor Gly Thr Thr 
6, Alpha-i Anti~rypsin Gly Thr Glu 
7, Chymotrypsin 
Inhibltor Gly Thr Glu 
8, Cl-lnhibitor Gly Val Glu 
9. Ova~bumln Gly Arg Glu 
iO, Angiotensinogen Glu Arg Glu 
q. ~13 q2 P~l P~o 
Ala Ala Ala 
Ala Thr Thr 
Ala Ala Ala 
Ala Set Set 
Ala Ala Giy 
Ala Set Ala 
Ala Ala Ala 
Val Val Gly 
Pro Thr Gla 
P9 P8  P7 
Set Thr Ala Val 
Val Thr Thr Val 
Ala Thr Sor lle 
s~r Thr A1. Vat 
Asp Thr Ala lie 
Ala Met Phe Leu 
Ala Thr Ala Val 
Ala Set Ala lie 
Set Ala Glu Ala 
Set Thr Gin Gin 
R~ae~ive 
Centor 
Val lle Ala Gly Arg Set Leu Asn P~o Asn 
Gly Phe Met Pro Leu Se~ Thr Gln Val Arg 
Ala Met Set Art Me~ Set Leu Sar S~r 
ne va~'s~ a~'A~ Mot Giu ci~ 
Thr Leu lle Pro Arg Ash Ala Leu Thr Ala 
Glu Ala lle Pro Met Set lle Pro P~o Glu 
Lys lie Thr Leu Leu Set Ala Leu ~al Glu 
Set Va~ Ala Arg Thr Leu Leu  Val Phe Glu 
Gly Val Asp Ala Ala Set Val Set Glu 
Leu Ash Lys P=o 
Fig, 1. Sequence alignment ofthe reactive centre loops of ten metnbcrs ofthe serpin family. The first 8 n~embers, including AT-Ill, are inhibitory 
serpins, Ovalbumin and angiotensinogen are non-inhibitory membersof the serpln fa n ly The boxed red on s aows the extent of conservation f 
small side~cl~ain drain0 acids at P,~-Pl~ amongst the active serpins, Note that this conservation is not maintairted in the non-inhibitoi'y sol:pins 
ovalbumin and anglotensinogen, The amino acid sequences of the serpins were aligned for maximum homology. 
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hydrophobicity, The results presented here sul~llest that hydrophoblc pockel (the lysine residue at position 191 
ellant~es in hydrophoblcity al position ~1t2 of AT.Ill 
play a role in the formation or stable inhibitory ¢om- 
plexe~ with e~.thrombin. Replacement of alanine-382 by 
strongly hydrophoblc residues resulted in comparable 
amounts of TAT comple,~ formation to that obtained 
with cell-free-derived normal AT.Ill, Size optimum ef. 
fects appear to be minimal since isoleucine, leucine and 
valine, wlaich are approximately 35-45% larller than 
alanine, gave TAT formation values imilar to wild type 
cell-free-derived normal AT-III, However, the replace- 
ment of alanine.382 by the strongly polar lysine residue 
completely eliminated'FAT formation, Althongh lysine 
and the strontlly Iwdrophobi¢ residues (isoleucine, 
lettcin¢, valine) have similar residue volumes, the 
hydrophobic differences between them are con. 
siderable. This change in hydrophobicity may, in part, 
explain the dramatic drop in TAT formation amonl~st 
these variants and is supported by previously reported 
data which P.re discussed below. 
Amongst he inhibitory serpins, the region P~z-P,~ (in 
AT-III this is represented by residues 382-385) consists 
of small side.chain amino acids, principally alanine, 
glycine and serine (Fig. 1). It has recently been sug- 
gested that this highly conserved region is necessary to 
provide flexibility of the N-terminal stalk of AT-III 
such that it has the ability to act as an inhibitory serpin 
[18,19]. It is postulated that once the reactive centre of 
AT-III has been cleaved by the serine protease, this N- 
terminal stalk of AT-Ill moves towards the underlying 
/.,-]-sheet (due to the flexible nature of the 382-385 
region) thereby allowing complex formation to occur. 
This concept ~s supported by the observations that the 
non-inhibitory serpins ovalbumin and angiotensinogen, 
considered to have large bulky side-chain residues in 
this region, fail to undergo the S.R transition, typical of 
the inhibitory serpins [20]. Thus, the substitution of 
threonine for alanine at position P~z in AT-Ill [5], 
which has been shown to convert AT-Ill into a 
substrate rather than an inhibitor of serine proteases 
[6], may act to after the flexibility of the Pt2-P9 region 
by interacting with additional adjacent amino acids via 
hydrogen bonding. The crystal structure of the cleaved 
form of the inhibitory serpin c~)-antitrypsin font-AT) 
shows that the alanine at position P~2, which is 
analogous to alanine-382 in AT-Ill, fits tightly into a 
hydrophobic pocket consisting of phenylalanine 
residues at position 51,190 and 384, and a methionine 
residue at position 374 [19,20]. When the amino acid se- 
quences of AT-Ill were aligned for maximum 
homology with at-AT, phenylalanine r sidues at posi- 
tions 77, 221 and 422 in AT-Ill lined up exactly as in 
a~-A'I'. The methionine r sidue at position 374 in a~-AT 
is replaced by an isoleucine residue ~.t he correslsonding 
position 412 in AT.Ill: In addition, lysine and arginine 
residues located at positions 222 and 413 respectively, in 
AT-lit would be positioned in close proximity, to this 
of m-AT is also ccmserved in AT-Ill}, Thus, strongly 
Iwdrophobic amino acid substitutions atposition 382 in 
AT-iI| would result in the maintenance or sertne pro- 
tease inhibitory activiw. The substitution of lysine at 
position 382 in AT.Ill likely would prevent movement 
or the cleaved N-terminal stalk into the /~.sheet, as 
described previously [18,19], However. a more pro- 
bable explanation is that the strongly hydroplaille 
nature of lysine, combined with its positive char~,e (at 
physiololtical pH) would not allow the N-terminal stalk 
to interact with the hydrophobic pocket in AT.Ill as 
described above [18-20]. Consequently, the substitu- 
tion of lysine at position 382 would convert AT-Ill 
from an inhibitor of thrombin to a substrate, Further- 
more, it is interesting to note that both the non- 
inhibitory .~erpins, ovalbumin and angiotensinogen, 
contain an arginine residue at position P~.~ (Fig, l). 
This, however, is not the case for the inhibitory serpins. 
This may imply that the presence of an arginine residue 
at this position could contribute to tl~e non.inhibitory 
nature of  serpins. 
The data presented here assumes that AT-Ill 
undergoes a similar S-R transition as described for 
oh-AT [20]. Confirmation of the positioning of the 
alanine 382 residue in the P~I-P9 region of AT-Ill, 
before and after cleavage by the target protease, must, 
however, await crystallographic data, Nonetheless, the 
present data suggest that impairment of serine protease 
inhibitory activity by mutations at position 382 in AT- 
Ill result from either: the increased stability (rigidity) of 
the Pt~.-P9 region of tl~e xposed reactive centre loop or; 
the inability of the anaino acid residue at position 382, 
upon cleavage, to interact with the conserved 
hydrophobic pocket consisting of three phenylalanine 
residues (at positions 77,221 and 422) and an isoleucine 
(position 412) residue. 
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